WO2003032963A2 - Method of reducing type 2 diabetes in high risk patients - Google Patents
Method of reducing type 2 diabetes in high risk patients Download PDFInfo
- Publication number
- WO2003032963A2 WO2003032963A2 PCT/EP2002/011636 EP0211636W WO03032963A2 WO 2003032963 A2 WO2003032963 A2 WO 2003032963A2 EP 0211636 W EP0211636 W EP 0211636W WO 03032963 A2 WO03032963 A2 WO 03032963A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diabetes
- converting enzyme
- angiotensin converting
- enzyme inhibitor
- individual
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to a method of reducing diabetes in patients who are at risk for developing diabetes comprising administering to such patients an effective amount of an angiotensin converting enzyme (ACE) inhibitor for sufficient period of time to prevent the development of diabetes in such patients; to a method of slowing or reversing the decline of ⁇ -cell function in an individual comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to prevent the decline of ⁇ -cell function in such individual; a method of increasing islet blood flow in an individual comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to increase islet blood flow in such individual; a method of increasing pancreatic ⁇ -cell perfusion in an individual comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for ' a sufficient period of time to increase pancreatic ⁇ -cell perfusion in such individual and a method of lowering aldosterone secretion and renal
- the present invention further relates to the use of an angiotensin converting enzyme (ACE) inhibitor or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the prevention or reduction of the onset of diabetes in patients who are at risk for developing diabetes; for the prevention, slowing or reversing the decline of ⁇ -cell function; for increasing islet blood flow; for increasing pancreatic ⁇ -cell perfusion; and for lowering aldosterone secretion and renal potassium wasting.
- ACE angiotensin converting enzyme
- ACE inhibitors are well known in the art for their activity in inhibiting angiotensin converting enzyme, thereby blocking conversion of the decapeptide angiotensin I to angiotensin II.
- the principal pharmacological and clinical effects of ACE inhibitors arise from suppression of synthesis of angiotensin II.
- Angiotensin II is a potent pressor substance and, therefore, blood pressure lowering can result from inhibition of its biosynthesis, especially in animals and humans whose hypertension is angiotensin II related.
- ACE inhibitors are effective antihypertensive agents in a variety of animal models and are clinically useful for the treatment of hypertension in humans.
- ACE inhibitors are also employed for the treatment of heart conditions such as congestive heart failure.
- ACE inhibitors are also useful for the prevention of diabetes in patients that are at high risk for developing diabetes.
- the present invention relates to a method of reducing diabetes in patients who are at risk for developing diabetes comprising administering to such patients an effective amount of an angiotensin converting enzyme (ACE) inhibitor for sufficient period of time to prevent the development of diabetes in such patients; to a method of slowing or reversing the decline of ⁇ -cell function in an individual comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to prevent the decline of ⁇ -cell function in such individual; a method of increasing islet blood flow in an individual comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to increase islet blood flow in such individual; a method of increasing pancreatic ⁇ -cell perfusion in an individual comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to increase pancreatic ⁇ -cell perfusion in such individual and a method of lowering aldosterone secretion and renal potassium
- the present invention further relates to the use of an angiotensin converting enzyme (ACE) inhibitor or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the prevention or reduction of the onset of diabetes in patients who are at risk for developing diabetes; for the prevention, slowing or reversing the decline of ⁇ -cell function; for increasing islet blood flow; for increasing pancreatic ⁇ -cell perfusion; and for lowering aldosterone secretion and renal potassium wasting.
- ACE angiotensin converting enzyme
- Type 2 diabetes is an important and common risk factor for the development of coronary artery disease, strokes, peripheral arterial disease, and renal and eye disease.
- the direct and indirect costs of diabetes and its complications exceeds $100 billion per year.
- This health and economic impact of diabetes is bound to increase, as the global prevalence of diabetes rises from 4.2% to 5.4% by the year 2025.
- diabetes as used herein includes both type I diabetes, also known as insulin-dependent, diabetes mellitus (IDMM), and type II diabetes, also known as non-insulin-dependent diabetes mellitus (NIDDM).
- IDMM insulin-dependent, diabetes mellitus
- NIDDM non-insulin-dependent diabetes mellitus
- ACE inhibitor angiotensin converting enzyme inhibitor
- Angiotensin I physiologically inactive decapeptide form of angiotensin
- Angiotensin II vasoconstrictive octapeptide form of angiotensin
- Example of ACE inhibitors suitable for use herein are for instance the following compounds: AB-103, ancovenin, benazeprilat, BRL-36378, BW-A575C, CGS- 13928C, CL242817, CV-5975, Equaten, EU-4865, EU-4867, EU-5476, foroxymithine, FPL 66564, FR-900456, Hoe-065, I5B2, indolapril, ketomethylureas, KRI-1177, KRI-1230, L681176, libenzapril, MCD, MDL-27088, MDL-27467A, moveltipril, MS-41 , nicotianamine, pentopril, phenacein, pivopril, rentiapril, RG-5975; RG-6134, RG-6207, RGH0399, ROO-911 , RS-10085-197/RS-2039, RS 5139, RS 86127, RU
- a group of ACE inhibitors of high interest are alacepril, benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, ramiprilat, saralasin acetate, temocapril, trandolapril, trandolaprilat, ceranapril, moexipril, quinaprilat and spirapril.
- ACE inhibitor ramipril Pharmaceutically acceptable derivatives of ACE inhibitors are understood to include physiologically tolerable salts of ACE inhibitors, such physiologically tolerable salts are understood as meaning both their organic and inorganic salts, such as are described in Remington's Pharmaceutical Sciences (17th Edition, page 1418 (1985)).
- acidic groups inter alia, sodium, potassium, calcium and ammonium salts are preferred; for basic groups, inter alia, salts of hydrochloric acid, sulfuric acid, phosphoric acid or of carboxylic acids or sulfonic acids, such as, for example, acetic acid, citric acid, benzoic acid, maleic acid, fumaric acid, tartaric acid and p- toluenesulfonic acid are preferred.
- basic groups inter alia, salts of hydrochloric acid, sulfuric acid, phosphoric acid or of carboxylic acids or sulfonic acids, such as, for example, acetic acid, citric acid, benzoic acid, maleic acid, fumaric acid, tartaric acid and p- toluenesulfonic acid are preferred.
- ACE inhibitors suitable for use herein or their pharmaceutically acceptable derivatives can be used in animals, preferably in mammals, and in particular in human, as pharmaceuticals per se, in mixtures with one another or in the form of pharmaceutical preparations.
- the present invention also relates to pharmaceutical formulations comprising as active ingredient at least one ACE inhibitor and/or an pharmaceutically acceptable derivative thereof in addition to customary pharmaceutically innocuous excipients and auxiliaries and their use in the prevention of diabetes or the decline of ⁇ -cell function, the increasing of islet blood flow or pancreatic ⁇ -cell perfusion and lowering aldosterone secretion and renal potassium wasting and the production of medicaments therefor.
- the pharmaceutical preparations normally contain 0.1 to 99 percent by weight, preferably 0.5 to 95 percent by weight, of the ACE inhibitor and/or an pharmaceutically acceptable derivative thereof.
- the pharmaceutical preparations can be prepared in a manner known per se.
- the ACE inhibitor and/or an pharmaceutically acceptable derivative thereof are brought, together with one or more solid or liquid pharmaceutical excipients and/or auxiliaries and, if desired, in combination with other pharmaceutical active compounds into a suitable administration form or dose form, which can then be used as a pharmaceutical in human medicine or veterinary medicine.
- compositions which contain an ACE inhibitor and/or an pharmaceutically acceptable derivative thereof can be administered orally, parenterally, intravenously, rectally or by inhalation, the preferred administration being dependent on the particular symptoms of the disorder.
- the ACE inhibitors and/or an pharmaceutically acceptable derivative thereof can be used here on their own or together with pharmaceutical auxiliaries, namely both in veterinary and in human medicine.
- auxiliaries which are suitable for the desired pharmaceutical formulation.
- auxiliaries which are suitable for the desired pharmaceutical formulation.
- solvents for example, antioxidants, dispersants, emulsifiers, antifoams, flavor corrigents, preservatives, solubilizers or colorants.
- the active compounds are mixed with the additives suitable therefor, such as excipients, stabilizers or inert diluents and are brought by means of the customary methods into the suitable administration forms, such as tablets, coated tablets, hard capsules, aqueous, alcoholic or oily solutions.
- suitable administration forms such as tablets, coated tablets, hard capsules, aqueous, alcoholic or oily solutions.
- Inert- excipients which can be used are, for example, gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose or starch, in particular corn starch. Preparation can take place here both as dry and as moist granules.
- Possible oily excipients or solvents are, for example, vegetable or animal oils, such as sunflower oil or codliver oil.
- the active compounds are brought into solution, suspension or emulsion, if desired with the substances customary therefor such as solubilizers, emulsifiers or other auxiliaries.
- Suitable solvents for example, are: water, physiological saline solution or alcohols, e.g. ethanol, propanol, glycerol, and additionally also sugar solutions such as glucose or mannitol solutions, or alternatively a mixture of the various solvents mentioned.
- compositions suitable for administration in the form of aerosols or sprays are, for example, solutions, suspensions or emulsions of the active compound of the formula I in a pharmaceutically acceptable solvent, such as, in particular, ethanol or water, or a mixture of such solvents. If required, the formulation can also contain other pharmaceutical auxiliaries such as surfactants, emulsifiers and stabilizers, and also a propellant.
- a pharmaceutically acceptable solvent such as, in particular, ethanol or water, or a mixture of such solvents.
- the formulation can also contain other pharmaceutical auxiliaries such as surfactants, emulsifiers and stabilizers, and also a propellant.
- Such a preparation customarily contains the active compound in a concentration from approximately 0.1 to 10, in particular from approximately 0.3 to 3, % by weight.
- the dose of the active compound to be administered and the frequency of administration will depend on the potency and duration of action of the compounds used; additionally also on the nature of the indication and on the sex, age, weight and individual responsiveness of the mammal to be treated.
- the daily dose in a patient weighing approximately 75 kg is at least 0.001 mg/kg, preferably 0.01 mg/kg, to about 20 mg/kg, preferably 1 mg/kg, of body weight.
- the ACE inhibitors and/or an pharmaceutically acceptable derivative thereof cafi also be used to achieve an advantageous theraupeutic action together with other pharmacologically active compounds for the prevention of the abovementioned syndromes.
- Hemoglobin A ⁇ c (HbA ⁇ c ) levels and medications used - among those diagnosed as having diabetes were also recorded.
- the HbAic levels ⁇ were determined locally. Values higher than 110% of the upper limit of normal for each laboratory were considered to be biochemical confirmation of diabetes.
- the proportion of patients taking study ramipril or open label ACE-inhibitors in the active group was 98.3% at 2 years and 89.7% at 4 years.
- the proportion taking open label ACE-inhibitors in the control group was 11.6% and 21.4% respectively New Diagnosis of Diabetes
- RR indicates relative risk
- Cl confidence interval
- MA microalbuminuria
- ON overt nephropathy
- ULN upper limits of normal
- primary event death, myocardial infarction, or stroke, t Controlling for primary events and development of MA or ON, new diabetes with glycated hemoglobin ⁇ 110 % had a 0.67 RR (95 % Cl, 0.52-0.86).
- TABLE 3 demonstrates the results among subgroups of patients with different risk factors for developing diabetes.
- the results are consistent among those with a waist to hip ratio below or above the median of 0.93 or less or higher than 0.93 and consistent among those with a body mass index (BMI) of 27.7 or less or higher than 27.7, those with or without a history of hypertension, those receiving or not receiving ⁇ -blockers or diuretics at randomization.
- BMI body mass index
- a higher proportion of individuals without diabetes who were randomized to the placebo group than those randomized to the ramipril group received diuretics or ⁇ -blockers (drugs that are associated with glucose intolerance or diabetes) during the study.
- the RR for diabetes in the subgroup of individuals who never took these drugs during the study was consistent with the overall results (RR, 0.62; 95% Cl, 0.43-0.90).
- Body mass index > 27.7 Kg/m 2 1095 63 (5.8) 1146 94 (8.2)
- ACE inhibitors may increase islet blood flow and pancreatic ⁇ -cell perfusion by reducing angiotensin-2 mediated vasoconstriction in the pancreas (Diabetologica. 1998; 41127-133). These effects may potentially slow or reverse the decline in ⁇ -cell function.
- ACE inhibitors may reduce insulin resistance in skeletal muscles (, increase insulin- mediated glucose disposal thereby decreasing the need for pancreatic insulin secretion.
- the increased insulin mediated glucose uptake by skeletal muscle in response to an ACE inhibitor is due to increased bradykinin-mediated nitric oxide production and not to reductions in angiotensin 2 production or action (Am J Physiol. 1999; 277:R332-R336; Br J Clin Pharmacol 1998; 46: 467-471 ).
- agents that increase nitric oxide may also increase insulin-mediated glucose uptake, which include that (1) both insulin-mediated vasodiiation and skeletal muscle glucose metabolism are reduced in obese persons who do not have diabetes (i.e., individuals at risk for diabetes) and in individuals with type 2 diabetes, (2) inhibition of nitric oxide production reproduces this effect in lean individuals, and (3) the effect on insulin sensitivity is greater than can be accounted for by just increased skeletal muscle blood flow (Am J Cardiol. 1999, 84: 25J-27J). ACE inhibitors may also reduce insulin resistance at the liver and fat cell, which would reduced hepatic glucose production and lower free fatty acid levels (Diabetolologia, 1991 ; 34:119-125).
- Type 2 diabetes is a growing clinical and public health problem. Preventive efforts related to lifestyle modification are not always successful; therefore, alternative prevention strategies need to be studied. Objective: To investigate the effectiveness of ramipril, an angiotensin-converting enzyme inhibitor, in preventing diabetes among high-risk persons.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/492,919 US20050065203A1 (en) | 2001-10-17 | 2002-10-17 | Method of reducing type 2 diabetes in high risk patients |
JP2003535767A JP2005531492A (en) | 2001-10-17 | 2002-10-17 | Method for reducing type II diabetes in high-risk patients |
IL16138802A IL161388A0 (en) | 2001-10-17 | 2002-10-17 | Method of reducing type 2 diabetes in high risk patients |
MXPA04003022A MXPA04003022A (en) | 2001-10-17 | 2002-10-17 | Method of reducing type 2 diabetes in high risk patients. |
CA002463682A CA2463682A1 (en) | 2001-10-17 | 2002-10-17 | Method of reducing type 2 diabetes in high risk patients |
EP02790295A EP1438043A2 (en) | 2001-10-17 | 2002-10-17 | Method of reducing type 2 diabetes in high risk patients |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34449501P | 2001-10-17 | 2001-10-17 | |
US60/344495 | 2001-10-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003032963A2 true WO2003032963A2 (en) | 2003-04-24 |
WO2003032963A3 WO2003032963A3 (en) | 2003-12-24 |
Family
ID=23350759
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/033213 WO2003032965A2 (en) | 2001-10-17 | 2002-10-17 | Use of ace inhibitors for reducing type 2 diabetes in high risk patients |
PCT/EP2002/011636 WO2003032963A2 (en) | 2001-10-17 | 2002-10-17 | Method of reducing type 2 diabetes in high risk patients |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/033213 WO2003032965A2 (en) | 2001-10-17 | 2002-10-17 | Use of ace inhibitors for reducing type 2 diabetes in high risk patients |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1438043A2 (en) |
JP (1) | JP2005531492A (en) |
AU (1) | AU2002335843A1 (en) |
CA (1) | CA2463682A1 (en) |
IL (1) | IL161388A0 (en) |
MX (1) | MXPA04003022A (en) |
WO (2) | WO2003032965A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004080482A2 (en) * | 2003-03-11 | 2004-09-23 | Institut De Cardiologie De Montréal / | Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure |
WO2005020984A2 (en) * | 2003-08-29 | 2005-03-10 | Aaipharma Inc. | Method of reducing the risk of oxidative stress |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008025450A1 (en) * | 2006-08-28 | 2008-03-06 | Sanofi-Aventis Deutschland Gmbh | Methods of lowering glucose levels |
CN108785265A (en) | 2013-03-14 | 2018-11-13 | 美国安进公司 | Heterocyclic compound and its purposes |
BR112015032410B8 (en) * | 2013-06-26 | 2021-10-26 | Dong A St Co Ltd | Use of a pharmaceutical composition comprising dpp-iv inhibitors in the preparation of a medicament for the prevention or treatment of kidney diseases |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0331014A2 (en) * | 1988-03-02 | 1989-09-06 | THERA - Patent Verwaltungs-GmbH | Use of ACE inhibitors in diabetes prophylaxis |
DE4308504A1 (en) * | 1993-03-18 | 1994-09-22 | Knoll Ag | New use of a combination of verapamil and trandolapril |
WO2001015674A2 (en) * | 1999-08-30 | 2001-03-08 | Aventis Pharma Deutschland Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
WO2001015673A2 (en) * | 1999-08-27 | 2001-03-08 | Aventis Pharma Deutschland Gmbh | Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure |
-
2002
- 2002-10-17 AU AU2002335843A patent/AU2002335843A1/en not_active Abandoned
- 2002-10-17 CA CA002463682A patent/CA2463682A1/en not_active Abandoned
- 2002-10-17 IL IL16138802A patent/IL161388A0/en unknown
- 2002-10-17 WO PCT/US2002/033213 patent/WO2003032965A2/en not_active Application Discontinuation
- 2002-10-17 MX MXPA04003022A patent/MXPA04003022A/en unknown
- 2002-10-17 JP JP2003535767A patent/JP2005531492A/en not_active Withdrawn
- 2002-10-17 WO PCT/EP2002/011636 patent/WO2003032963A2/en not_active Application Discontinuation
- 2002-10-17 EP EP02790295A patent/EP1438043A2/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0331014A2 (en) * | 1988-03-02 | 1989-09-06 | THERA - Patent Verwaltungs-GmbH | Use of ACE inhibitors in diabetes prophylaxis |
DE4308504A1 (en) * | 1993-03-18 | 1994-09-22 | Knoll Ag | New use of a combination of verapamil and trandolapril |
WO2001015673A2 (en) * | 1999-08-27 | 2001-03-08 | Aventis Pharma Deutschland Gmbh | Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure |
WO2001015674A2 (en) * | 1999-08-30 | 2001-03-08 | Aventis Pharma Deutschland Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
Non-Patent Citations (10)
Title |
---|
"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators." LANCET. ENGLAND 22 JAN 2000, vol. 355, no. 9200, 22 January 2000 (2000-01-22), pages 253-259, XP002232380 ISSN: 0140-6736 * |
BAKRIS GEORGE L ET AL: "ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure" KIDNEY INTERNATIONAL, NEW YORK, NY, US, vol. 58, no. 5, November 2000 (2000-11), pages 2084-2092, XP001164193 ISSN: 0085-2538 * |
CARLSSON P-O ET AL: "Angiotensin II and the endocrine pancreas: Effects on islet blood flow and insulin secretion in rats" DIABETOLOGIA 1998 GERMANY, vol. 41, no. 2, 1998, pages 127-133, XP001148412 ISSN: 0012-186X * |
GALLETTI F ET AL: "CONTROLLED STUDY OF THE EFFECT OF ANGIOTENSIN CONVERTING ENZYME INHIBITION VERSUS CALCIUM-ENTRY BLOCKADE ON INSULIN SENSITIVITY IN OVERWEIGT HYPERTENSIVE PATIENTS: TRANDOLAPRIL ITALIAN STUDY (TRIS)" JOURNAL OF HYPERTENSION, CURRENT SCIENCE, PHILADELPHIA, PA, US, vol. 17, no. 3, March 1999 (1999-03), pages 439-445, XP008014000 ISSN: 0263-6352 * |
JANKA H U ET AL: "Metabolic effects of ramipril treatment in hypertensive subjects with non-insulin-dependent diabetes mellitus." ARZNEIMITTEL-FORSCHUNG. GERMANY, WEST APR 1990, vol. 40, no. 4, April 1990 (1990-04), pages 432-435, XP001109698 ISSN: 0004-4172 * |
KEILANI T ET AL: "Selected aspects of ACE inhibitor therapy for patients with renal disease: impact on proteinuria, lipids and potassium" JOURNAL OF CLINICAL PHARMACOLOGY, LIPPINCOTT CO, HAGERSTOWN, MD, US, vol. 35, no. 1, January 1995 (1995-01), pages 87-97, XP008021110 ISSN: 0091-2700 * |
KR]TZFELDT J ET AL: "Ramipril increases the protein level of skeletal muscle IRS-1 and alters protein tyrosine phosphatase activity in spontaneously hypertensive rats." NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY. GERMANY JUL 2000, vol. 362, no. 1, July 2000 (2000-07), pages 1-6, XP001148413 ISSN: 0028-1298 * |
TAHMASEBI M ET AL: "THE TISSUE RENIN-ANGIOTENSIN SYSTEM IN HUMAN PANCREAS" JOURNAL OF ENDOCRINOLOGY, BRISTOL, GB, vol. 161, no. 2, 1999, pages 317-322, XP008014002 ISSN: 0022-0795 * |
YUSUF S ET AL: "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators." THE NEW ENGLAND JOURNAL OF MEDICINE. UNITED STATES 20 JAN 2000, vol. 342, no. 3, 20 January 2000 (2000-01-20), pages 145-153, XP008013952 ISSN: 0028-4793 * |
YUSUF S ET AL: "RAMIPRIL AND THE DEVELOPMENT OF DIABETES" JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, CHICAGO,IL, US, vol. 286, no. 15, 17 October 2001 (2001-10-17), pages 1882-1885, XP008013945 ISSN: 0098-7484 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004080482A2 (en) * | 2003-03-11 | 2004-09-23 | Institut De Cardiologie De Montréal / | Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure |
WO2004080482A3 (en) * | 2003-03-11 | 2004-11-11 | Inst Cardiologie Montreal | Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure |
WO2005020984A2 (en) * | 2003-08-29 | 2005-03-10 | Aaipharma Inc. | Method of reducing the risk of oxidative stress |
WO2005020984A3 (en) * | 2003-08-29 | 2005-09-09 | Aaipharma Inc | Method of reducing the risk of oxidative stress |
Also Published As
Publication number | Publication date |
---|---|
CA2463682A1 (en) | 2003-04-24 |
EP1438043A2 (en) | 2004-07-21 |
AU2002335843A1 (en) | 2003-04-28 |
JP2005531492A (en) | 2005-10-20 |
IL161388A0 (en) | 2004-09-27 |
WO2003032965A2 (en) | 2003-04-24 |
WO2003032965A3 (en) | 2003-11-27 |
WO2003032963A3 (en) | 2003-12-24 |
MXPA04003022A (en) | 2004-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2378018C2 (en) | Pharmaceutical preparations and their application for prevention of stroke, diabetes and/or congestive heart failure | |
AU2009200746B2 (en) | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events | |
CA2904447C (en) | Therapy for complications of diabetes | |
ZA200503542B (en) | Pharmaceutical combination of telmisartan and atovastatin for the prophylaxis of treatment of cardiovascular, cardiopulmonary, pulmanory or renal diseases | |
TWI539949B (en) | Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats | |
WO1994028924A1 (en) | Combination of angiotensin converting enzyme inhibitors and aii antagonists | |
CN102076337A (en) | Use of dronedarone for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level due to dronedarone administration | |
WO2003032963A2 (en) | Method of reducing type 2 diabetes in high risk patients | |
EP0808172B1 (en) | Combination of angiotensin converting enzyme inhibitor and aldosterone antagonist for the treatment of ventricular hypertrophy | |
US20050065203A1 (en) | Method of reducing type 2 diabetes in high risk patients | |
CA3134786A1 (en) | Methods for treating subjects with chronic kidney disease | |
Fricker et al. | Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects | |
AU2002362897A1 (en) | Method of reducing type 2 diabetes in high risk patients | |
Fatourechi et al. | A practical guideline for management of hypertension in patients with diabetes | |
EP1414421B1 (en) | The treatment of lipodystrophy with inhibitors of the renin angiotensin system | |
AU2002319535A1 (en) | The treatment of lipodystrophy | |
Giles et al. | An evaluation of the efficacy of olmesartan medoxomil in Black patients with hypertension |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/003022 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002790295 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 161388 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2463682 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002362897 Country of ref document: AU Ref document number: 2003535767 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002790295 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10492919 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002790295 Country of ref document: EP |